Vazoaktif İlaçlar
Özet
Vazoaktif ilaçlar, damar tonusunu ve kardiyak debiyi etkileyerek şok yönetiminde kullanılan, vazopresörler ve inotroplar olmak üzere iki ana sınıfa ayrılan farmakolojik ajanlardır. Vazopresörler vazokonstriksiyon yoluyla ortalama arter basıncını artırırken, inotroplar kalbin kontraktilitesini artırır. Bu ilaçlar etkilerini alfa-1, beta-1, beta-2 adrenerjik, dopaminerjik, vazopressin ve anjiyotensin reseptörleri gibi farklı reseptör mekanizmaları üzerinden gösterirler. Septik şokta ilk seçenek olarak güçlü vazokonstriktör etkisi olan norepinefrin tercih edilirken; alternatif olarak fenilefrin, epinefrin, efedrin, dopamin ve vazopressin gibi çeşitli vazopresörler de klinik duruma göre kullanılır. Dobutamin, isoproterenol, fosfodiesteraz inhibitörleri ve kalsiyum duyarlılaştırıcı levosimendan ise kalp debisini artırmak için kullanılan başlıca inotropik ajanlardır. Vazoaktif ilaç tedavisi, hastanın komorbiditelerine, şokun etiyolojisine ve fizyolojik özelliklerine göre bireyselleştirilmeli; intra-arteriyel izlem ile ortalama arteriyel basınç (MAP) ve doku perfüzyon parametreleri (laktat klirensi, idrar çıkışı) yakından takip edilmelidir. Bu güçlü ajanların kullanımı aritmiler, miyokardiyal iskemi, ekstremite ve organ hipoperfüzyonu ile hiperglisemi gibi ciddi komplikasyonlara yol açabileceğinden, hemodinamik stabilizasyon sağlanır sağlanmaz dozları kademeli olarak azaltılarak tedavi sonlandırılmalıdır.
Vasoactive drugs are pharmacological agents used in shock management that affect vascular tone and cardiac output, categorized into two main classes: vasopressors and inotropes. While vasopressors increase mean arterial pressure through vasoconstriction, inotropes enhance cardiac contractility. These drugs exert their effects through various receptor mechanisms, including alpha-1, beta-1, beta-2 adrenergic, dopaminergic, vasopressin, and angiotensin receptors. Norepinephrine, a potent vasoconstrictor, is the first-choice agent in septic shock, whereas other vasopressors such as phenylephrine, epinephrine, ephedrine, dopamine, and vasopressin are preferred based on specific clinical scenarios. Dobutamine, isoproterenol, phosphodiesterase inhibitors, and the calcium sensitizer levosimendan represent the primary inotropic agents utilized to increase cardiac output. Vasoactive therapy must be highly individualized based on patient comorbidities, shock etiology, and physiological characteristics, requiring close monitoring of mean arterial pressure (MAP) and tissue perfusion markers, such as lactate clearance and urine output, via intra-arterial tracking. Because these potent agents can trigger severe complications, including arrhythmias, myocardial ischemia, extremity or organ hypoperfusion, and hyperglycemia, their doses should be tapered and discontinued as soon as hemodynamic stabilization is achieved.
Referanslar
Manaker s.(2020) Use of vasopressors and inotropes, https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes (03.07.2020)
Altıntaş ND, İskit Topeli A. Vazoaktif ve inotropik ilaçların doğru kullanımı. Yoğun Bakım Derg. 2006; 6: 179-190
Goodman and Gilman’s (2011) Pharmacological Basis of Therapeutics Twelfth (ed). New York
Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle. Am J Physiol. 1994; 266:H2462.
Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833–46.
Catt KJ, Mendelsohn FA, Millan MA, et al. The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol. 1984; 6 Suppl 4:S575.
Martin C, Saux P, Eon B,et al. Septic shock: a goaldirected therapy using volume loading, dobutamine and/or norepinephrine. Acta Anaesthesiol Scand. 1990;34:413–417.
Schreuder WO, Schneider AJ, Groeneveld ABJ, et al. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Chest. 1989;95:1282–1288
Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med. 1993;19:151–154.
Ruokonen E, Takala J, Kari A, et al. Regional blood flow and oxygen transport in septic shock. Crit Care Med. 1993;21:1296–1303.
Levy B, Bollaert PE, Charpentier C,et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med. 1997;23:282–287.
Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock. 1986;18:141–155
Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32:1928–1948
Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 2000;28:2758–2765.
De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med. 2003;31:1659–1667
Nguyen HB, Rivers EP, Abrahamian FM, et al; Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med. 2006 Jul;48(1):28-54.
Hollenberg, S.M.J.C., Vasopressor support in septic shock. Chest. 2007. 132(5):1678-1687.
Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle. Am J Physiol. 1994 Jun;266(6 Pt 2):H2462-7.
Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med. 1982 Jul;10(7):432-5.
Allwood, MJ, Cobbold AF, Ginsburg J. Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. J British Medical Bulletin. 1963. 19: 132-136.
Givertz, M., et al., Approach to the patient with hypotension and hemodynamic instability. J Irwin Rippe’s Intensive Care Medicine. 7th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams 2012: 307-317.
Kee V.R., Hemodynamic pharmacology of intravenous vasopressors. J Critical care nurse. 2003. 23(4):79-82.
Hoffman, Basic.J.B. and c. pharmacology, Adrenoceptor activating & other sympathomimetic Drugs. J Basic clinical pharmacology, 1998: p. 118-135.
Morgan P. The role of vasopressors in the management of hypotension induced by spinal and epidural anaesthesia. Can J Anaesth. 1994 May;41(5 Pt 1):404-13.
Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med. 1974; 291:707
Horwıtz D, Fox SM 3D, Goldberg LI. Effects of Dopamine in man. Circ Res. 1962; 10:237.
Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy. 1986; 6:304.
Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med. 1994; 22:1919.
Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990; 18:S56.
Cooper BE., Review and update on inotropes and vasopressors. J AACN Advanced critical care. 2008. 19(1): 5-13.
Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med. 1995; 23:1962.
Levy M.M., Evans LE, Rhodes A. The surviving sepsis campaign bundle:2018 update. J Intensive care medicine. 2018. 44(6): 925-928.
Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576-582
Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887.
Schmittinger CA, Torgersen C, Luckner G, et al. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950-958.
Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med. 2012; 38:9.
Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 2010; 36:57
Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med. 2004; 32:1327.
Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med. 2002; 30:1899.
Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002; 30:2548.
Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003; 31:1394.
Russell JA. Bench-to-bedside review: vasopressin in the management of septic shock. Crit Care. 2011;15(4):226.
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2): 580-637.
Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183(7):847-855
Torgersen C, Dunser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 2010;36(1):57-65.
Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med. 2007;35(10):2280-2285.
Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313-2319.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001; 27(8):1416-1421.
Tayama E, Ueda T, Shojima T, et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007;6(6): 715-719
Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Medicine. 2006;32(11):1782-1789.
Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13(4):R130.
Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest. 2012;142(3):593-6
Jeon Y, Ryu JH, Lim YJ, et al. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinoneinduced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg. 2006;29(6):952-956.
Yimin H, Xiaoyu L, Yuping H, Weiyan L, Ning L. The effect of vasopressin on the hemodynamics in CABG patients. J Cardiothorac Surg. 2013;8:49.
Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). Crit Care. 2018; 22:131.
Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med. 2002; 30:1899.
Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002; 30:2548.
Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol. 2002; 39:1269.
Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990; 18:S56.
Antonucci E, Fiaccadori E, Donadello K, et al. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care. 2014;29:500-11.
Tomioka T, Shimada S, Ito Y, et al. Myocardial depression induced by severe sepsis: successful rescue using extracorporeal cardiopulmonary resuscitation from initial phase of severe sepsis. BMJ Case Rep. 2015;2015.
Zangrillo A, Putzu A, Monaco F, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. J Crit Care. 2015;30:908-13
Zhang Z, Chen K. Vasoactive agents for the treatment of sepsis. Ann Transl Med. 2016 Sep;4(17):333.
Rauch H, Motsch J, Böttiger BW. Newer approaches to the pharmacological management of heart failure. Curr Opin Anaesthesiol. 2006;19:75-81.
Sperry JL, Minei JP, Frankel HL. Early use of vasopressors after injury: caution before constriction. J Trauma.2008; 64(1):9–14
Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726–1734
Marik PE, Mohedin M . The contrasting efects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA . 1994;272(17):1354–1357
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200
van Diepen S, Katz JN, Albert NM et al (2017) Contemporary manage ment of cardiogenic shock: a scientifc statement from the American heart association. Circulation. 2017;136(16):e232–e268.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
National Guideline Centre (UK). Sepsis: Recognition, Assessment and Early Management. London: National Institute for Health and Care Excellence (UK); 2016 Jul. PMID: 27441326.
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016; 316(5):509-518.
Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36(6):1701–1706
Hollenberg SM. Inotrope and vasopressor therapy of septic shock. Crit Care Clin. 2009;25(4):781–802
De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362:779.
LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000 Aug;28(8):2729-32.
Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: efects on oxygen variables and renal function. Crit Care Med. 2005;33:780–786
Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure targets in patients with septic shock. N Engl J Med. 2014;370:1583–1593
Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994; 330(24):1717–1722
Jones AE, Shapiro NI, Trzeciak S,et al. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010 Feb 24;303(8):739-46.
Jansen TC, van Bommel J, Schoonderbeek FJ, et al. LACTATE study group: early lactate-guided therapy in intensive care unit patients: A multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182:752–761
Teboul JL, Saugel B, Cecconi M, et al. Less invasive hemodynamic monitoring in critically ill patients. Intensive Care Med. 2016; 42:1350–1359
Cecconi M, De Backer D, Antonelli M, et al. Consensus on circula tory shock and hemodynamic monitoring. task force of the European society of intensive care medicine. Intensive Care Med. 2014; 40:1795–1815
Merouani M, Guignard B, Vincent F, et al. Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. Crit Care. 2008;12:R155
Hammond DA, McCain K, Painter JT, et al. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. J Intensive Care Med. 2017:885066617714209
Bissell BD, Magee C, Moran P, et al. Hemody namic instability secondary to vasopressin withdrawal in septic shock. J Intensive Care Med. 2017:34(9):761-765.
Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobu tamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370(9588):676–684
Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Crit Care Med. 2009;37(3):811–818
Myburgh JA, Higgins A, Jovanovska A, et al. CAT Study investigators. A comparison of epineph rine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226–2234
Annane D, Sébille V, Duboc D, et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 1998;178(1):20–25
Bohr DF. Adrenergic receptors in coronary arteries. Ann N Y Acad Sci. 1967; 139:799-807.
Day NP, Phu NH, Bethell DP,et al. The effects of dopamine and adrenaline infusions on acid–base balance and systemic haemodynamics in severe infection. Lancet. 1996;348:219–223
Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med. 1991; 19:1395.
Dalimonte MA, DeGrado JR, Anger KE. Vasoactive Agents for Adult Septic Shock: An Update and Review. Journal of Pharmacy Practice. 2020;33(4):523-532.
